Q-omics provides the consensus-scored TM9SF4 profile across patient tissues and cancer cell-line models. TM9SF4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, TM9SF4 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, TM9SF4 protein abundance shows 20,413 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, BLCA, and GBM as cancer lineages where TM9SF4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TM9SF4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TM9SF4 survival associations across molecular data types. TM9SF4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TM9SF4 RNA expression–survival associations across cancer types. High TM9SF4 expression shows unfavorable associations in LIHC, BLCA, UVM, KIRP, MESO and LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for TM9SF4 RNA expression.
This table summarizes TM9SF4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TM9SF4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TM9SF4 shows higher tumor expression in BLCA, HNSC, LUAD, KIRC, STAD and COAD. The BLCA box plot shows higher TM9SF4 RNA expression in tumor versus normal tissue (log2 FC = +0.845, t-test p < 0.001).
This table shows molecular features associated with TM9SF4 in patient tissues and cancer cell lines. In patient samples, TM9SF4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TM9SF4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
